Jazz Pharmaceuticals Presents Overall Survival And Longer Follow-Up Data From HERIZON-BTC-01 Trial Evaluating Zanidatamab In Previously Treated HER2-Positive Biliary Tract Cancer At ASCO 2024

Press/Media

Period1 Jun 2024

Media coverage

108

Media coverage